Mass Tort brief
Bellwether Acceleration and Settlement Machinery
Accelerated bellwether schedules, critical Daubert scientific gatekeeping, and corporate settlement structures squeeze corporate defendants across federal dockets.
Mass Tort
A federal judge rejected Lyft's regulatory shield defense — preserving common-law safety duties and clearing 136 sexual assault lawsuits for trial.
BackgroundHundreds of female passengers filed civil tort actions alleging ride-hailing platforms failed to institute adequate driver vetting, biometric monitoring, and safety protections. The Judicial Panel on Multidistrict Litigation consolidated federal passenger assault lawsuits against Lyft in Northern California.
- Judge Lin indicated that regulatory inaction by state utility commissions does not displace common-law duties of care owed by transportation networks.
- Plaintiffs presented evidence showing Lyft failed to deactivate drivers facing prior sexual harassment complaints, exposing subsequent passengers to assault.
- Denying Lyft's dismissal motion will clear approximately 136 consolidated federal passenger lawsuits to enter comprehensive expert discovery.
Mass Tort
A $40M catheter fracture verdict accelerated the Bard PowerPort court calendar — piling immense pressure on Becton Dickinson to negotiate a global settlement.
BackgroundMultidistrict litigation consolidates thousands of similar federal civil lawsuits before a single judge to streamline discovery and conduct representative bellwether trials. Over 4,140 lawsuits allege Becton Dickinson manufactured port catheters with excessive barium sulfate that caused catastrophic vascular fractures.
- The third bellwether trial in Phoenix is examining catheter infection risks, testing whether device design flaws contributed directly to life-threatening patient sepsis.
- September's $40 million jury award marked the first fracture liability finding against C.R. Bard, shifting trial leverage decisively toward injured plaintiffs.
- Defense attorneys are challenging expert engineering testimony on silicone degradation in an effort to curb exposure to punitive damages before December.
Mass Tort
With 12,000 cases pending, narrowing the hair relaxer MDL to five bellwethers sets up a decisive Daubert showdown over endocrine cancer science.
BackgroundNational Institutes of Health studies linked frequent use of chemical hair straightening products with significantly elevated risks of uterine malignancies. Cosmetic manufacturers including L'Oréal, Revlon, and Godrej maintain that their products are thoroughly tested and scientifically safe.
- Expert witness discovery closes on December 21, setting up critical Rule 702 Daubert scientific causation hearings before Judge Rowland in early 2027.
- The court set the first federal bellwether trial for September 7, 2027, rejecting defense motions to pause ongoing discovery proceedings.
- Judge Rowland lifted discovery stays against secondary cosmetic distributors while plaintiffs probe corporate restructuring moves executed by L'Oréal to ringfence liabilities.
Mass Tort
Federal judges are deciding whether gastroparesis science meets courtroom standards — a ruling that will make or break 4,000 Ozempic injury claims.
BackgroundFederal judges act as Daubert gatekeepers, excluding unreliable or speculative expert scientific testimony before lawsuits can proceed to jury trials. Novo Nordisk and Eli Lilly argue that delayed gastric emptying is a documented pharmacological mechanism, not permanent stomach paralysis.
- Plaintiffs presented gastrointestinal motility studies arguing that prolonged GLP-1 receptor agonist use triggers irreversible bowel blockages and chronic gastroparesis.
- Drugmakers argued that preexisting diabetic autonomic neuropathy accounts for plaintiffs' gastroparesis symptoms, urging the court to dismiss the entire docket.
- A parallel federal MDL alleging GLP-1 treatments cause ischemic optic neuropathy and vision loss grew to 247 centralized actions.
Mass Tort
Mass Tort
Mass Tort
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.
